ERBB2 and breast cancer: An in vivo study confirmed this synergy relationship in xenograft models of HER2+/ER+ BC refractory to trastuzumab, with a significant improvement in tumor regression by combining abemaciclib with tratuzumab (p = 0.0012) +/− tamoxifen in comparison with abemaciclib alone [83].